Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome

The objective of this randomized triple blind controlled trial is to compare the effects of Doxepin and Nortriptyline on diarrhea predominant irritable bowel syndrome. In this stuy, 75 patients with IBS are randomly assigned to receive Doxepin , Nortriptyline or placebo, a tablet per day, orally, for two months. Abdominal pain, mucus in the stool, incomplete evacuation, and bloating are measured and compared between groups at the baseline and one and two month after the intervention.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Irritable Bowel Syndrome Colonic Diseases Colonic Diseases, Functional Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Gastrointestinal Research center,Beheshti Hospital

Qom, Qom Province, 1677859642, Iran

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Presence of diarrhea predominant irritable bowel syndrome according to ROME criteria

Exclusion criteria

Gastrointestinal bleeding
More than 5% weight loss in the last 6 months
Presence of any finding in favor of organic disorders in the lab tests or organic disorder in colonoscopy of high risk patients

Treatment and study plan

Doxepin

Drug

Nortriptyline

Drug

Placebo

Drug

Sponsors and collaborators

Lead sponsor

Qom University of Medical Sciences

Other

Collaborators

Young Researchers Club

Registry information

Important dates

First posted: Dec 31, 2010
Registry last updated: Dec 31, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed